MENLO PARK, Calif. — September 3, 2025 — Leads & Copy — PacBio (NASDAQ: PACB) and EpiCypher are collaborating to bring EpiCypher’s CUTANA® Hia5 enzyme to market for use with Fiber-seq assays on PacBio HiFi sequencing systems, offering researchers a new method to study chromatin biology at single-molecule resolution. Fiber-seq, or single-molecule chromatin fiber sequencing, is an advanced multi-omic whole genome sequencing assay that simultaneously measures chromatin accessibility, DNA methylation, and DNA variation on individual DNA molecules.
The collaboration enables researchers to explore DNA regulation at the level of individual molecules, interrogate complex regions of the genome, and consolidate multiple assays into one workflow. EpiCypher’s Hia5 enzyme is now commercially available for use in Fiber-seq assays on PacBio’s HiFi sequencing systems.
David Miller, VP of Global Marketing at PacBio, stated that the partnership with EpiCypher advances the role of PacBio sequencing in epigenomics. Martis Cowles, PhD, Chief Business Officer at EpiCypher, added that the collaboration enables researchers to generate single-molecule insights for decoding gene regulation.
The CUTANA Hia5 enzyme is commercially available from EpiCypher in 8 and 24 reaction formats (15-1032-8RXN and 15-1032-24RXN) with a supported Fiber-seq protocol.
Contacts:
Todd Friedman, ir@pacificbiosciences.com
pr@pacificbiosciences.com
Source: PacBio
